FATE241220P6000
- 3.30
- 0.000.00%
Fate Therapeutics Newsroom
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $3 to $10
Fate Therapeutics Analyst Ratings
Barclays Releases a Buy Rating on Fate Therapeutics (FATE)
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $5 to $6
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO) and Fate Therapeutics (FATE)
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $5 to $10
Analysts Conflicted on These Healthcare Names: McKesson (MCK), Fate Therapeutics (FATE) and Voyager Therapeutics (VYGR)
Fate Therapeutics Analyst Ratings
Fate Therapeutics (FATE) Receives a Buy From Barclays
TD Cowen Sticks to Its Hold Rating for Fate Therapeutics (FATE)
Fate Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Fate Therapeutics, Maintains $5 Price Target
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $5
Fate Therapeutics: Hold Rating Amid Financial Stability and Upcoming Milestones
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Fate Therapeutics (FATE)
Leerink Partners Maintains Fate Therapeutics(FATE.US) With Buy Rating
Fate Therapeutics' Promising Outlook: Buy Rating on Innovative Cell Therapy Programs FT819 and FT522
Fate Therapeutics (FATE) Gets a Hold From Stifel Nicolaus
Fate Therapeutics: Hold Rating Amidst Steady Q2 Financials and Clinical Progress
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $5 to $10